Use of Factor IX Complex in Warfarin-related Intracranial Hemorrhage

Boulis, Nicholas M.; Bobek, Miroslav P.; Schmaier, Alvin H.; Hoff, Julian T.

doi:10.1097/00006123-199911000-00020

Cited by 195 publications

(178 citation statements)

References 7 publications

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…In contrast, a larger study by Sjoblom et al could not show any improvement in outcomes with the different agents given. 11 Similarly, Boulis et al, 31 Huttner et al 32 and Cartmill et al 33 showed PCC produced a rapid reversal in coagulopathy but without improvements in clinical outcomes. Recently, Japanese investigators 22 reported better outcomes in those treated with PCC compared with a control group.…”

Section: Discussionmentioning

confidence: 97%

“…PCC and vitamin K, without concurrent FFP, can rapidly reverse the coagulopathy, 5,25,[31][32][33] and some authors suggest that the PCC/vitamin K combination may be sufficient to reverse life-threatening bleeding. 25,36 However, the three-factor PCC used in our institution (Prothrombinex-HT 37 ) may not contain sufficient factor VII, and given the dire consequences of inadequate reversal, this is covered by using small volumes of FFP.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Warfarin‐related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates

Hanger

Geddes

Wilkinson

et al. 2013

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Warfarin‐related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates

Hanger

Geddes

Wilkinson

et al. 2013

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…2,9,11) In the present series, patients taking warfarin received reversal agents such as human factor IX complex concentrate, fresh frozen plasma, and/or vitamin K.…”

Section: Discussionmentioning

confidence: 98%

“…The conventional treatment with fresh frozen plasma and vitamin K often fails to achieve the desired correction of coagulopathy in urgent neurosurgical settings. 2,9,11) Recombinant coagulation factor VIIa or human factor IX complex concen-Neurol Med Chir (Tokyo) 51, December, 2011 H. Oyama et al…”

Section: Discussionmentioning

confidence: 99%

Acute Subdural Hematoma in Patients With Medication Associated With Risk of Hemorrhage

Oyama

Kito

Maki

et al. 2011

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

The characteristics of 90 cases of acute subdural hematoma were analyzed in 25 patients taking medication related to bleeding tendency, the bleeding tendency group, and 65 patients without such medication, the control group. Acute subdural hematoma was significantly associated with over-turning or without accident in the bleeding tendency group (92%) compared with the control group (56.9%). The time from trauma to admission was significantly longer in the bleeding tendency group (32.7 hours) compared with the control group (9.7 hours). The mean Glasgow Coma Scale score on admission was 13.0 points in the bleeding tendency group and was significantly better than 10.9 points in the control group. The international normalized ratio of prothrombin time on admission was 3.59 in the patients treated with warfarin. All patients taking warfarin received reversal agents and this value decreased significantly to 1.38. In the bleeding tendency group, hematoma size increased in 20% after the operation, almost the same as in the control group (25%). Although good recovery tended to be observed less frequently in the bleeding tendency group than in the control group, the mean age of the bleeding tendency group was significantly higher than that of the control group, so the prognosis might be affected by this age-related factor. Cautious diagnosis, follow-up imaging, and strict management are mandatory in patients with bleeding tendency.

show abstract

“…Although prothrombin protein concentrate works rapidly and has a lower volume of administration, available data do not indicate it is clinically superior to fresh-frozen plasma. 33,34 The ongoing randomized PROTECT trial (NCT00618098), comparing fresh-frozen plasma and four-factor prothrombin protein concentrate for reversal of vitamin K antagonist therapy, may provide further insight.…”

Section: Clinical Risk Factors For Strokementioning

confidence: 99%

Selecting antithrombotic therapy for patients with atrial fibrillation

Tanaka-Esposito

Chung

2015

CCJM

View full text Add to dashboard Cite

When considering anticoagulant therapy for patients with atrial fibrillation, one must balance the reduction in risk of thromboembolism that this therapy offers against the risk of bleeding that it poses. The American Heart Association, American College of Cardiology, and Heart Rhythm Society updated their atrial fibrillation guidelines in 2014. This review outlines a rationale for clinical decision-making based on the new guidelines and summarizes the currently approved drugs.

show abstract

Use of Factor IX Complex in Warfarin-related Intracranial Hemorrhage

Abstract: The use of FIXCC accelerated correction of warfarin-related anticoagulation in the presence of intracranial hemorrhage.

Cited by 195 publications

References 7 publications

Warfarin‐related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates

Warfarin‐related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates

Acute Subdural Hematoma in Patients With Medication Associated With Risk of Hemorrhage

Selecting antithrombotic therapy for patients with atrial fibrillation

Contact Info

Product

Resources

About